Most Read Articles
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).

Angiopoietin-2 predicts prognosis in lung cancer

09 Oct 2017
Lung cancer patients have new hope thanks to an experimental treatment has been proven to be more effective

Serum concentrations of angiopoietin-2 (Ang-2) appear to predict the tumour staging and prognosis of patients with lung cancer, according to a new systematic review and meta-analysis.

After the selection criteria were applied, 20 studies, corresponding to 1,911 patients, were eligible for inclusion. Of these, the nine that evaluated the relationship between Ang-2 levels and disease progression showed a positive significant association between serum Ang-2 levels and tumour stage.

Specifically, a significant difference in Ang-2 levels was observed between stage 1 tumours and stages 2 (standardized mean difference [SMD], -0.51; 95 percent CI, -0.75 to -0.27; p<0.001), 3 (SMD, -0.83; -1.44 to -0.21; p=0.009) and 4 (SMD, -1.51; -2.59 to -0.42; p=0.006) tumours.

Ang-2 serum levels were also significantly different between stage 2 tumours and stages 3 (SMD, -0.52; -0.80 to -0.244; p<0.001) and 4 (SMD, -1.21; -1.98 to -0.44; p=0.002) tumours. Stages 3 and 4 tumours also differ in Ang-2 levels (SMD, -0.58; -0.93 to -0.23; p=0.001).

Serum Ang-2 concentrations were also significantly higher in lung cancer patients with lymph node involvement (SMD, 1.06; 0.57 to 1.56; p<0.001).

The role of Ang-2 on disease prognosis was examined in seven studies which included 575 patients. In these, significantly worse prognosis was associated with high serum Ang-2 levels (hazard ratio [HR], 1.64; 1.20 to 2.25; p=0.002).

Subgroup analysis by type of lung cancer showed that elevated Ang-2 levels were a risk factor for poor prognosis in patients with non-small cell lung cancer (HR, 1.44; 1.07 to 1.93; p=0.017) and small cell lung cancer (HR, 2.29; 1.46 to 3.59; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).